<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676336</url>
  </required_header>
  <id_info>
    <org_study_id>16VBHB</org_study_id>
    <nct_id>NCT02676336</nct_id>
  </id_info>
  <brief_title>A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioPharmX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioPharmX, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo controlled, multi-center study to evaluate the
      safety, tolerability and potential effects of dietary supplement Violet™ Iodine on breast
      health in women with cyclic breast discomfort and tenderness to eliminate the evaluation of
      effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in self assessed cyclic breast discomfort</measure>
    <time_frame>After 6 months of active treatment with molecular iodine (I2) compared to placebo</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fibrocystic Breast Condition (FBC)</condition>
  <arm_group>
    <arm_group_label>Violet™ Iodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3mg molecular iodine (I2) daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3mg placebo daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-over</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on placebo will be offered 3 months of active post-treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Violet™ Molecular Iodine (I2)</intervention_name>
    <arm_group_label>Violet™ Iodine</arm_group_label>
    <arm_group_label>Cross-over</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy premenopausal females ≥ 18 years of age

          -  BMI 20.0 - 29.9 kg/m2 (± 1 kg/m2)

          -  Females of childbearing potential must agree to use a reliable and consistent method
             of birth control in the Investigator's opinion, excluding depot contraceptives and
             Explanon, and have a negative urine pregnancy test result. Hormonal contraceptives
             such as oral contraceptives, birth control patch (Ortho Evra), vaginal contraceptive
             ring (NuvaRing) are all acceptable as long as the subject is on a stable dose and
             agrees not to change during the study period

          -  No apparent health conditions that in the investigator's opinion would interfere with
             study participation, compliance or interpretation of endpoints or would not be in the
             best interest of the subject

          -  Moderate to severe cyclic breast discomfort of at least 4 days per month (discomfort
             ≥4 on a 0-10 scale)

          -  No known medical or psychological condition that in the investigator's opinion could
             interfere with study participation

          -  Agrees to comply with all study related procedures and visits including access to a
             smartphone (Android or iOS) and ability to enter daily diary information via a smart
             phone app

          -  Capable of reading and understanding study related materials (in English or French)
             and has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          -  Women who are pregnant, breast feeding, or planning to become pregnant during the
             course of the trial

          -  Perimenopausal or irregular menstrual cycles

          -  Women who have had an oophorectomy

          -  Known thyroid condition or currently taking any thyroid medications

          -  Prior bariatric surgery or other interventions or medications that might affect
             gastric pH

          -  Use of iodine supplementation, Tamoxifen, Lupron, or Danazol, in the last 6 months

          -  Clinically significant abnormal laboratory results at Screening

          -  Breast implant surgeries that have not fully healed or have ongoing problems
             associated with the implant (i.e. seroma, infection etc.)

          -  Planned elective surgeries to occur during participation in the study

          -  Known allergy or sensitivity to study product ingredients (e.g. Iodine)

          -  History of alcohol or drug abuse within the past year

          -  Use of medicinal marijuana within the past year

          -  Participation in a clinical research trial within 30 days prior to randomization or
             plans to participate in any other study during the next 11 months

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent

          -  Any other condition which in the Investigator's opinion may adversely affect the
             subject's ability to complete the study or its measures, may confound interpretation
             of study outcome measures (such as another condition) or which may pose significant
             risk to the subject
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KGK Synergize</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Synergize</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FBC</keyword>
  <keyword>cyclic mastalgia</keyword>
  <keyword>breast discomfort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrocystic Breast Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

